VoiceOver users please use the tab key when navigating expanded menus

Vaccines, volatility and eventualities

 

Miles Workman

Senior Economist

ANZ New Zealand Ltd.

Summary

 

Recent headlines about the Pfizer and BioNTech vaccine have been met with a sharp rally in risk, as markets bet that successful virus containment may soon be approaching.

 

Our economic outlook has maintained a running assumption about how the pandemic, and its eventual containment, will evolve.

 

We discuss how recent developments align with our assumptions, and how speedier progress would influence our outlook.

 

The view

 

What do epidemiologists and economists have in common? The names of our professions start with an “E” and end with “ist” but that’s about it.

 

The former are the ones who really understand the pandemic (and the degree of uncertainty around its evolution), but it’s the latter who need to make assumptions about when virus risks will be contained to a point that borders can reopen, and businesses and households will feel more confident about their income prospects.

 

The recent vaccine headlines are very exciting, but how should we be thinking about this in terms of the economic outlook? Regarding the evolution of the pandemic, our economic outlook assumes the following:

 

  • By late 2020 to early 2021 we will begin getting positive news on the vaccine and treatment front.

 

  • By mid-2021 we’ll see the initial manufacture and distribution of a vaccine/s and/or treatment/s (scale uncertain).

 

  • By late 2021 to early 2022 there will have been sufficient inoculation or advancement on the testing and treatment front for New Zealand to open its borders to the rest of the world. International tourism resumes, with some initial pent-up demand, but weaker foreign household incomes and possibly residual safety concerns associated with travel weighing after that. Nonetheless, the economic recovery picks up pace.

 

So, how does the recent news flow compare to this time-line? At face value, the reports from Pfizer and BioNTech suggest it’s all happening a little earlier than expected, encouragingly. Nonetheless, we must be cautious.

 

Safety testing, approval, the scale of manufacture, and distribution hurdles all still need be overcome.

 

So at this early stage, we’re awaiting further news before making wholesale changes to the above assumptions.

 

But here’s hoping! If vaccine developments are speedier than our assumptions, there are three key channels through which it could impact our outlook:

 

  • It brings forward the assumed border reopening, and the return of international tourism and foreign students.

 

  • The good news (including an end to the ever-present threat of mini lockdowns) puts firms more in the mood to hire and invest, and makes households more willing to spend.

 

  • Earlier global containment paves the way to a stronger-than-otherwise global economy, which will benefit demand for our exports, supporting the terms of trade and national incomes.
  •  

 

"Markets may well have gotten a bit over-excited and overlooked the nuance, as markets tend to do, but that’s not to detract from the scientific achievements we’re seeing"

Miles Workman, Senior Economist, ANZ New Zealand.

 

 

And if this were looking likely (perhaps by the end of Q1 2021), then the case for taking the OCR negative would be greatly reduced!

 

But the reality could be less of a light switch than one might think – more of a steady brightening in the outlook.

 

Even once the hurdles to delivering a safe, effective vaccine are overcome, border reopening may happen in a relatively gradual manner as policy makers tread cautiously.

 

Further, gains to economic momentum via the confidence channel may be slow moving, given the industries really feeling the pain of a closed border won’t really enter expansionary mode until they start receiving bookings and international travel is normalising.

 

And just because vaccine risks are under control that doesn’t mean central bankers can declare ‘job done’ and look towards rapid normalisation of policy settings.

 

While it is possible that the rebound to full employment and building inflation pressures is swift, because of “economic scarring” that’s typically not how recoveries play out. We expect very gradual policy normalisation.

 

  • Deflationary risks are significant, and central banks have limited ammunition to tackle this. Central banks have therefore expressed some tolerance for a small inflation overshoot on the other side, as tightening too early could expose economic vulnerabilities, causing inflation pressures and expectations to erode at pace. And once inflation expectations become unanchored, the Reserve Bank’s job would become very difficult.

 

  • Employment typically lags economic activity, as businesses tend to require certainty before making the decision to add to headcount. This can be amplified by labour market regulations that increase labour costs and make it difficult for businesses to flex labour input in response to changing demand. New Zealand regulations are relatively stringent, and that’s likely to slow the return to full employment. 

 

  • Further, the economy will be a lot more sensitive to rising interest rates on the other side of this crisis, given the increase in debt we’re seeing. The Government’s taken most of it on the chin, but households are leveraging up too, and some businesses will also have needed to borrow more to get through. In fact, higher debt levels across the broader economy (and globe) are going to be one of the legacies of COVID-19. And that’s likely to make any path of monetary policy normalisation a relatively lengthy and gentle one.

 

Despite the long road ahead, recent vaccine news is fantastic and could mark the proverbial “beginning of the end”.

 

And thank goodness. Recent virus developments in much of the Northern Hemisphere are looking truly grim, and humanity needs some light at the end of the tunnel.

 

Markets may well have gotten a bit over-excited and overlooked the nuance, as markets tend to do, but that’s not to detract from the scientific achievements we’re seeing.

 

As virus developments evolve, we’ll be looking out for a sustained pickup in business sentiment, and in particular investment and hiring intentions, as well as a downward shift in the infection rate in North America and Europe.

 

An indication that people are happy to travel. And of course, health policy decisions here in NZ, and in particular, the gradual reopening of the border.

 

Our outlook has always included the assumption that virus risks will eventually be contained; now we wait for more information that may allow us to tweak the assumed timing and magnitude of its boost to activity.

 

Downside risks haven’t gone away, unfortunately, but it’s great to see them countered by some solid upside developments.

RELATED ARTICLES

Making Sense of the Reserve Bank's Bag of Tricks

With the OCR near zero, the RBNZ has had to work with a new bag of tricks since the COVID-19 crisis hit. This explainer make sense of how these tools work and affect the economy.

Spring Shopping Splurge - the Winners and Losers

ANZ's credit and debit card spending figures for October show some retail sectors are doing well well and others are struggling.

Could Prefab Solve NZ's Housing Crisis?

Leading architect and Grand Designs NZ host Chris Moller has called for more women to enter the construction sector, and for NZ to massively scale up the pre-fabrication of homes.